<div id="readability-page-1"><p>MacroGenics, Inc. (NASDAQ:MGNX - Get Free Report) was the target of a significant drop in short interest in April. As of April 15th, there was short interest totaling 2,928,196 shares,  a drop of 22.5% from the March 31st total of 3,778,755 shares. Based on an average daily trading volume, of 979,052 shares, the days-to-cover ratio is currently 3.0 days. Currently, 5.3% of the shares of the stock are sold short.</p><h2>Wall Street Analysts Forecast Growth</h2><p>Several equities analysts have weighed in on MGNX shares. Barclays raised their target price on shares of MacroGenics from $4.00 to $6.00 and gave the company an &#34;overweight&#34; rating in a report on Monday, April 20th. B. Riley Financial upgraded MacroGenics from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and upped their price objective for the company from $3.00 to $9.00 in a research report on Friday, April 10th. Zacks Research lowered MacroGenics from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Thursday, January 1st. Citigroup  reiterated a &#34;market perform&#34; rating on shares of MacroGenics in a research report on Tuesday, February 24th. Finally, Wall Street Zen raised shares of MacroGenics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, March 14th. Three equities research analysts have rated the stock with a Buy rating, four have issued  a Hold rating and one  has issued  a Sell rating to the company. According to data from MarketBeat.com, MacroGenics presently has a consensus rating of &#34;Hold&#34; and an average target price of $5.40.</p><p><b>Check Out Our Latest Research Report on MGNX</b></p><h2>MacroGenics Stock Down 1.8%</h2><p>Shares of NASDAQ MGNX traded down $0.06 during midday trading on Wednesday, hitting $2.96. The stock had a trading volume of 97,249 shares, compared to its average volume of 1,019,032. The company has a fifty day moving average price of $2.84 and a 200 day moving average price of $2.05. The company has a market capitalization of $187.82 million, a price-to-earnings ratio of -2.53 and a beta of 1.09. MacroGenics has a 1-year low of $1.18 and a 1-year high of $3.88. </p><p>MacroGenics (NASDAQ:MGNX - Get Free Report) last announced its quarterly earnings results on Monday, March 9th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.42) by $0.20. MacroGenics had a negative net margin of 49.91% and a negative return on equity of 120.19%. The firm had revenue of $41.23 million for the quarter, compared to analysts' expectations of $27.81 million.  On average, research analysts forecast that  MacroGenics will post -1.2 EPS for the current year. </p><h2>Hedge Funds Weigh In On MacroGenics</h2><p>A number of institutional investors and hedge funds have recently bought and sold shares of MGNX. Jefferies Financial Group Inc. acquired a new position in shares of  MacroGenics during the fourth quarter worth $2,964,000.  Renaissance Technologies LLC increased its stake in  MacroGenics by 71.0% during the 4th quarter. Renaissance Technologies LLC now owns 2,908,631 shares of the biopharmaceutical company's stock worth $4,683,000 after buying an additional 1,207,408 shares during the period.  Marshall Wace LLP lifted its holdings in  MacroGenics by 104.0% in the 4th quarter. Marshall Wace LLP now owns 1,284,563 shares of the biopharmaceutical company's stock worth $2,068,000 after buying an additional 655,028 shares in the last quarter.  Jane Street Group LLC grew its stake in shares of  MacroGenics by 207.7% during the second quarter. Jane Street Group LLC now owns 758,204 shares of the biopharmaceutical company's stock valued at $917,000 after acquiring an additional 511,777 shares in the last quarter.  Finally, Affinity Asset Advisors LLC acquired a new position in shares of  MacroGenics in the fourth quarter worth about $780,000. Hedge funds and other institutional investors own  96.89% of the company's stock. </p><h2>MacroGenics Company Profile</h2> (Get Free Report)<p>MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody–based therapeutics for the treatment of cancer and autoimmune diseases. The company leverages proprietary Fc engineering technologies to enhance immune engagement and extend the activity of its antibodies. Since its founding in 2000, MacroGenics has advanced several product candidates through clinical trials, most notably margetuximab, a HER2-targeted antibody designed to improve outcomes in patients with HER2-positive breast cancer.  </p><p>Central to MacroGenics' research platform are its ADAPTIR and Trident bispecific antibody technologies.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than MacroGenics</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in MacroGenics Right Now?</h2><p>Before you consider MacroGenics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MacroGenics wasn't on the list.</p><p>While MacroGenics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

MGNX

<p>MacroGenics, Inc. (NASDAQ:MGNX) experienced a 22.5% decline in short interest in April, totaling 2,928,196 shares as of April 15th. Currently, 5.3% of shares are short sold, with a short-interest ratio of 3.0 days based on an average trading volume of 979,052 shares. Analysts have mixed ratings, with Barclays raising the target price to $6.00 and B. Riley upgrading to a buy rating with a target of $9.00. The stock is currently trading at $2.96, down 1.8%, with a market cap of $187.82 million and a negative EPS of -$0.22 for the last quarter.</p>

Market Beat

Macrogenics

VG Health

iShares US Pharma

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

iShares Biotechnology ETF

VanEck Biotech ETF

Direxion S&P Biotech Bear 3X

Direxion S&P Biotech Bull 3X

Invesco Nasdaq Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Health Care Select Sector SPDR

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

ALPS Medical Breakthrough

Fidelity Nasdaq Composite Index ETF

Nasdaq

NASDAQ Composite Index

Invesco QQQ Trust

Barclays

Barclays ETN+ Select MLP

Zacks Small/Mid Cap ETF

Zacks Quality International ETF

Zacks Focus Growth ETF

Nano Labs

Citigroup

Financial Street

Rimini Street

Charter Hall Long WALE REIT

Jefferies Financial

Jefferson Capital

AMPLITECH GROUP INC. C/WTS 19/02/2026(TO PUR COM)

Renasant

Rein Therapeutics

Global Interactive Tech

Marshalls plc

John Marshall Bancorp

Cushman & Wakefield

Cross Marketing Group, Inc.

AllianzIM US Large Cap Buffer10 Jan ETF

TrueShares Structured Outcome Jan ETF

Affinity Bancshares

Arcadian Asset

Brown Advisory US Smaller Companies PLC GBP

B Riley Financial Pref Share RILYL 7.375 Perp 09/04/25 B

B Riley Financial Pref Share RILYG 7.25 12/21/27

B Riley Financial Pref Share RILYN 6.5 09/30/2026

B Riley Financial Pref Share RILYK 5.5 03/31/26

B Riley Financial Pref Share RILYP 6.875 Perp 10/07/24

B Riley Financial Pref Share RILYZ 5.25 08/31/28

B Riley Financial Pref Share RILYT 6.0 01/31/28

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Charter Hall Retail REIT

Charter Hall Group

Charter Hall Social Infrastructure REIT

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

AmpliTech

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

MacroGenics, Inc. (NASDAQ:MGNX) Short Interest Down 22.5% in April